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Abstract
Telemedicine may support individual care plans in people with chronic obstructive pulmonary disease (COPD), potentially impro-
ving the clinical outcomes. To-date there is no clear evidence of benefit of telemedicine in this patients. The aim of this study is 
to provide an update on the effectiveness of telemedicine in reducing adverse clinical outcomes. 
We searched the Pubmed database for articles published between January 2005 and December 2014. We included only rando-
mized controlled  trials exclusively focused on patients with COPD and with a telemedicine intervention arm. Evaluated outcomes 
were number of exacerbations, ER visits, COPD hospitalizations, length of stay and death. We eventually included 12 randomized 
controlled trials. Most of them had a small sample size and was of poor quality, with a wide heterogeneity in the parameters and 
technologies used. Most studies reported a positive effect of telemonitoring on hospitalization for any cause, with risk reductions 
between 10% and 63%; however only three studies reached statistical significance. The same trend was observed for COPD-re-
lated hospital admission and ER visits. No significative effects of telemedicine was evidenced in reducing length of hospital stay, 
improving quality of life and reducing deaths. 
In conclusion, our study confirms that the available evidence on the effectiveness of telemedicine in COPD does not allow to draw 
definite conclusions; most evidence suggests a positive effect of telemonitoring on hospital admissions and ER visits. More trials 
with adequate sample size and with adequate consideration of background clinical services are needed to definitively establish 
its effectiveness.
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Introduction
Chronic Obstructive Pulmonary Disease 
(COPD) is one of the most prevalent disease 
worldwide. The clinical course is characterized 
by progressive decline in health status, punc-
tuated by acute respiratory exacerbations [1]. 
These exacerbations have a negative impact on 
patient prognosis, with progressive disability 
and increased health care resource use [2,3].
In COPD patients with a previous or recent 
history of exacerbations, current guidelines rec-
ommend education and case management in 
order to prevent severe acute exacerbations and 
to reduce COPD-related hospitalizations [4]. 
Furthermore, strategies aimed to identify and man-
age exacerbations at early stages are also needed in 
order to prevent hospitalizations, improve quality 
of life and to reduce health care cost [5].
Recently, due to an increased accessibility 
to and lower costs of information and commu-
nication technologies (ICT), telehealth applied 
to both acute and chronic disease has received 
great attention from the scientific community. 
Telehealth is defined “the provision of personal-
ized health care from a distance”. Other terms are 
used in this field; in particular “telemedicine” is 
often reserved for clinical and patient care appli-
cations [6]. The ultimate goal of telemedicine is to 
improve clinical management and quality of life 
of patients with chronic disease with consequent 
reduction of health costs [7].
In the latest years, a wide array of telemed-
icine applications have been developed, using 
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different devices (telephone, computer, or wear-
able and not wearable devices) . These applica-
tions are able to collect several parameters such 
as peripheral oxygen saturation, body weight, 
temperature by means of dedicated devices 
able to directly transmit data, or commercial 
measuring devices (e.g., pulse-oxymeter) that 
are connected to a transmitting device (e.g., a 
cellular telephone) that acts as a “gateway” to 
transmit the data. In some instances, the read-
ings are obtained using a commercial device 
and the information is manually transmitted 
by the patients, for example by punching it on 
a keyboard connected to a transmitting device. 
Data transmission can be synchronous or asyn-
chronous with data collection. The information 
transmitted by the telemonitoring systems are 
usually evaluated by healthcare professionals, 
such as doctors or nurses. In case of abnormal 
readings or when scheduled measurements 
were missing, a pre-specified protocol is put in 
action to respond to the situation. In some cases, 
telemonitoring systems can generate alerts to 
warn the personnel when readings are outside 
a specified range of normality.
In theory, telemedicine may help to better 
assist patients with physical limitations, and 
those who need frequent evaluation of their 
health status. Furthermore, in conditions char-
acterized by exacerbations, such as COPD, it 
may help to detect these events earlier, with 
more timely treatment and reduction of risk of 
adverse clinical outcome. Telemedicine may also 
foster greater patient self-management and less 
costly interventions [8]. Many trials have been 
performed to assess the effectiveness of telemon-
itoring in COPD patients to reduce health care 
resources consumption and health care costs, 
and to improve quality of life. The results of 
these studies, however, have been conflicting, 
and to-date, there is no clear evidence benefit 
of telemonitoring in COPD.
The aim of this study is to provide an up-
date on the available data published in the last 
10 years on the effectiveness of telemedicine in 
COPD in reducing emergency room (ER) visits, 
hospitalizations and deaths and in improving 
quality of life.
Methods
This systematic review is performed ac-
cording with PRISMA guidelines. We searched 
the Pubmed database for articles published 
between January 2005 and December 2014. 
The MeSH keywords used were “telemedicine” 
and “COPD”. Titles and abstracts of studies 
matching our search strategy were screened 
and the potentially eligible ones were obtained 
in full text for evaluation. The bibliography of 
selected studies were also searched to retrieve 
additional articles.
In order to reduce heterogeneity, we limit-
ed our review to randomized controlled  trials 
exclusively focused on patients with COPD and 
with a telemedicine intervention arm, defined as 
delivery of health services via remote telecom-
munications. Studies including only telerehabil-
itation or self-management or teleconsultation 
were excluded. Articles published in languages 
different than English were also excluded.
The outcomes we took into account were 
number of exacerbations, ER visits , COPD hos-
pitalizations, length of stay, and death. We also 
looked at quality of life and patients’ satisfaction.
Results
Literature search and studies general 
characteristics
The literature search identified 182 po-
tentially relevant papers. After reviewing the 
titles and abstracts, 50 were selected for a 
closer examination. 38 articles were excluded 
because they did not satisfy inclusion crite-
ria. Twelve randomized controlled trials were 
eventually included in our review (Figure 1). 
A summary of the key characteristic of all 12 
trials is shown in Table 1. Most studies were 
performed in Spain (5 papers). Almost all trials 
were monocentric.
38 articles did not meet
inclusion criteria
182 titles and abstracts
were identified from Pubmed
50 articles were identified
for full-text examination
12 trials were included
in the review
132 abstract discarded
because they did not
meet inclusion criteria
Figure 1. Study flow diagram
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Table 1. Characteristics of included studies
Study Country N Mean age 
(sd) 
Control / 
interven-
tion
COPD 
stage
Technology Measured parame-
thers
Type of intervention
Casas 
2006 [10]
Spain
-Belgium
155 72 (9)/ 70 
(9)
All Telephone (Web
-based call center)
None Comprehensive patient assessment 
with  weekly phone calls during first 
month to reinforce self-management
Accessibility to a specialized nurse 
case manager through a web-based 
call center who could access to 
patients records; if necessary, plan-
ning non-scheduled home visits
de Toledo 
2006 [20]
Spain 157 72 (8)/ 71 
(8)
All Support for video-
conference
Computer with In-
ternet connection
Health questionnaire
Spirometry
Patients could contact the call center 
for technical or health problems.  
In case of health problems  
10 questions were asked to assess 
illness severity
Regular nurse home visits, with 
access to on-line patient's clinical 
informations and doing a spirometry 
Garcia- 
-Aymerich 
2007 [11]
Spain 113 73 (9)/ 72 
(10)
All Telephone (Web
-based call center)
None Comprehensive patient assessment 
with weekly phone calls during first 
month to reinforce self-management
Specialized nurse case manager 
available through a web-based call 
center who could access to patients 
records; if necessary, planning of 
non-scheduled home visits
Koff  
2009 [17]
USA 40 65(8.2)/ 
66.6 (9.1)
GOLD 
stage 
3–4
Technology plat-
form used to enter 
and transmit re-
sults using home 
telephone line
Symptoms-based 
questions
FEV1
6-min walking test
Oxygen saturation
Daily data collection; patients could 
call in case of problems
Data checked by a respiratory the-
rapist
In case of alert therapist called  the 
primary care physician
Lewis 
 2010 [14]
United 
Kingdom
40 73/ 70 Modera-
te-seve-
re COPD
Handheld telemo-
nitor connected 
with medical de-
vices; data trans-
mission via inter-
net connection
Questions about 
chest over the prece-
ding day or night
Temperature
Oxygen saturation
Data recorded twice a day, trans-
mitted to a website accessible to 
the Team
Automatic email message to Team 
in case of alerts, with subsequent  
call to the patient or message issu-
ed through the monitor's screen
Antoniades 
2012 [18]
Australia 44 68 (9)/70 
(10)
Modera-
te-seve-
re COPD
Laptop computer 
with digitally inte-
grated health de-
vices with internet 
connection
Spirometry
Weight
Temperature
Blood pressure
Oxygen saturation
Electrocardiogram
Sputum color and 
volume
Symptoms
Medication usage
Daily parameters measurement, 
with possibility to record symptoms 
and change of medication ,  
reviewed by a nurse
In case of a clinical alert the nurse 
could call the patient or local doctor
Chau 
2012 [13]
China 40 72.22 
(6.13)/73.5 
(6.05)
Modera-
te-seve-
re COPD
Mobile phone 
connected with 
medical devices
Oxygen saturation
Heart rate
Respiratory rate
First nurse home visit for all groups 
participants with self-care education
Patients collected clinical data three 
times a day, sent to on-line platform, 
monitored by a nurse
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De San 
Miguel  
2013 [15]
Australia 80 74/ 71 COPD 
with do-
miciliary 
oxygen
HealtHub (portable 
unit with display) 
connected to tele-
phone line
Blood pressure
Weight
Temperature
Heart rate
Oxygen saturation
Question related 
to general state of 
health
Daily parameter measurement, auto-
matically transmitted via telephone 
to a secure Web site, daily monito-
red by a nurse
Generation of alert in case of para-
meter alteration or missing data: 
the nurse contacted the participants 
over the telephone and recommend 
a GP visit if necessary
Jòdar- 
-Sànchez 
2013 [21]
Spain 45 71 (10)/ 74 
(8)
COPD 
with 
chronic 
respi-
ratory 
failure in 
LTO
Medical devices 
connected to the 
patient's home 
telephone line
Every day:
Oxygen saturation 
(daily)
Heart rate (daily)
Blood pressure (daily)
Spirometry (2/week)
Daily data collection, sent to the Call 
Centre
In case of alert call center contacted 
patient; if confirmed, generation of 
therapeutic strategy
Pedone 
2013 [12]
Italy 99 75.4 (6.7)/ 
74.1 (6.4)
GOLD 
stage 
II-III
Mobile phone 
connected via 
bluetooth to a 
pulse-oxymeter 
and a wristband 
that contained 
sensors for clinical 
parameter me-
asurement; data 
transmission via 
telephone
Oxygen saturation
Heart rate
Near-body tempe-
rature
Overall physical 
activity
Data measured every three hours 
during the day,  evaluated daily by a 
physician skilled in respiratory care;
Alert generation in case  of parame-
ter alteration: physician contacted 
telephonically patients for check and 
therapeutic strategy
Pinnock 
2013 [16]
United 
Kingdom
256 68.4 (8.4)/ 
69.4 (8.8)
All Touch screen tele-
monitoring equip-
ment connected to 
the patient's home 
telephone line
Daily questionnaire 
about symptoms and 
treatment use
Oxygen saturation
Daily data recording,  monitored by 
the supporting clinical team
In case of clinical alerts , the team 
contacted the patient by telephone 
to undertake clinical assessment for 
patient management
Segrelles 
Calvo 
 2014 [19]
Spain 60 72.7 (9.3)/ 
75 (9.7)
Severe 
o very 
severe 
COPD 
with 
long-term 
home 
oxygen 
therapy
Medical devices 
with  automatic 
data transmission 
via a  modem 
through patient's 
telephone line
Blood pressure (daily)
Oxygen saturation 
(daily)
Heart rate (daily)
Peak expiratory flow 
(3/week)
Daily parameters measurement, 
transmitted to a Clinical Monitoring 
Center
In case of alert, a nurse contacted 
the patient and eventually esca-
lated to Pneumologist for manage-
ment.
Abbreviations: COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in the 1st second; GP: general practitioner; LTO: long-term oxygen therapy 
Trials were published in 8 different journals; 
8 studies were published in Journal of Telemedi-
cine and Telecare, Telemedicine and e-HEALTH, 
Respiratory Medicine and European Respiratory 
Journal (2 studies each). Inclusion criteria were 
very heterogeneous, the GOLD stages selected 
differed across studies, and a recent history of 
hospitalization for COPD-exacerbation was not 
required by all trials. Exclusion criteria were 
heterogeneous as well, but most studies excluded 
patients with cognitive impairment or in pallia-
tive care.
In general, the sample size of the studies was 
small (5 trials have less than 50 participants). 
Table 1 cd. Characteristics of included studies
Mean age range varied from 65 to 73 years. The 
follow-up period ranged from 20 days to 1 year. 
Five trials included only moderate-severe or 
severe COPD. Educational intervention were 
utilized in 5 studies, in 3 studies it was offered to 
both arms, in the others only to the intervention 
group. The outcomes most frequently studied 
were hospital readmissions, ER visits, patient 
satisfaction, and quality of life.
The quality of the studies evaluated accord-
ing to the Cochrane Guidelines [9] was at best fair. 
As it was expected in studies on this topic, no 
study used masking of the treatment allocation. 
Blinded outcome assessment and statistical analy-
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Table 2. Risk of bias in the included studies.
First author Random 
sequence 
generation
Allocation 
concealment
Blinding of 
participants 
and person-
nel
Blinding of 
outcome as-
sessment
Incomplete 
outcome 
data
Selective 
reporting
Other sour-
ces of bias
Casas 
2006 [10]
L L Not blinded U L L H
de Toledo 
2006 [20]
U U U U U L L
Garcia-Aymerich 
2007 [11]
L L Not blinded U H H L
Koff 
2009 [17]
H U Not blinded Not blinded L L L
Lewis 
2010 [14]
L L U U U L L
Antoniades 
2012 [18]
L L U U L L L
Chau 
2012 [13]
H U Not blinded Not blinded L L H
De San Miguel  
2013 [15]
L L Not blinded Not blinded H H L
Jòdar-Sànchez 
2013 [21]
U U U U H L L
Pedone 
2013 [12]
U U Not blinded Not blinded L L L
Pinnock 
2013 [16]
L L U L L L L
Segrelles Calvo  
2014 [19]
H U Not blinded Not blinded L H L
Criteria defined for quality assessment are based on the Cochrane guidelines [9]. 
Abbreviations: H, high risk of bias; L, low risk of bias; U, unclear or unrevealed risk of bias.
sis was not used by all studies, and in some cases 
it was not possible to ascertain whether blinding 
assessment was used or not. Furthermore, in 
some studies the outcome data were selectively 
reported (Table 2).
Telemonitoring characteristics
There was a noticeable heterogeneity in the 
technologies used. In some cases [10,11], informa-
tion was obtained by a nurse using questionnaires 
in telephone interviews, in others [12,13] a mo-
bile phone were used to transmit data collected 
using commercially available devices. In some 
instances, a portable unit including measuring 
devices acted as measuring and transmitting 
device [14–16]. Data were transmitted using the 
Internet in eight trials, the broadband mobile 
phone connection in two trials; while two trials 
used telephone interviews.
In all studies a health care professional (e.g. 
nurse) monitored the collected data. The data 
collected and the action taken in response to ab-
normal readings varied across studies. The data 
collected ranged from health questionnaires only 
to multiparametric data collection, including spi-
rometry or peak expiratory flow. The parameters 
most frequently used for telemonitoring were 
peripheral oxygen saturation (9 trials), health 
status questionnaires (6 trials) and heart rate 
(5 trials). The action taken could be follow-up 
telephone calls, calls by a nurse with access to 
patients’ personal records [10,11], home visits, or 
scheduling of ambulatory visits or hospital admis-
sion, depending on the severity of abnormalities 
in monitored parameters. In most instances, the 
telemonitoring systems were equipped with al-
gorithms that could generate an alert in case of 
change in measured parameters or in case of loss 
of data measurement for one or more days.
Effect on hospital admissions
This outcome was evaluated in 8/12 includ-
ed studies (Table 3), with results not completely 
comparable because of differences in the asso-
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Table 3. Studies outcomes: differences between telemedicine vs control group 
First author All causes 
readmis-
sions
COPD-rela-
ted readmis-
sions
Length of 
stay
ER visits Deaths QoL Satisfaction
Casas 2006 [10] Improved* – – – Worsened – –
de Toledo 2006 [20] Improved* – – Improved Worsened – –
Garcia-Aymerich 2007 [11] – Improved* – – – Not modified –
Koff 2009 [17] – Improved – Improved – Improved* Improved
Lewis 2010 [14] – – – – – Not modified Improved
Antoniades 2012 [18] Improved Improved Not modified – – Improved –
Chau 2012 [13] – Worsened Worsened Worsened – Not modified Improved
De San Miguel 2013 [15] Improved Improved Improved Improved – – Improved
Jòdar-Sànchez 013 [21] Worsened – Worsened Improved – Improved Improved
Pedone 2013 [12] Improved – – – – – –
Pinnock 2013 [16] Not modified Improved Improved – Improved Not modified –
Segrelles Calvo 2014 [19] Improved* – Improved* Improved* Improved – Improved
ER: emergency room; QoL: quality of life; *: statistically significant.
ciation measures used. Two studies [13,17] only 
reported data on COPD-related admission. Most 
studies (6/10) reported a positive effect of telemon-
itoring on hospitalization for any cause, with risk 
reductions between 10% [18] and 40% [15], with 
the noticeable exception of Segrelles et al. that 
reported a risk reduction of 63% [19]. In only three 
of these positive studies [10,19,20],  however, the 
results reached statistical significance. One study 
[21] reported an increase in hospitalizations in 
the telemonitored group, with an average number 
of hospitalizations per patients in the follow-up 
period (4 months) of 0.38 in the telemonitoring 
group and 0.14 in the control group.
Effect on COPD-related hospital 
admissions
Half of the included studies evaluated this 
outcome (Table 3). Most of them (4/6) reported 
a reduction in number of COPD-related hospi-
talizations, with a risk reduction ranging from 
14% [18] to 69% [17]; no study, however, reached 
statistical significance. Only Chau et al. [13] re-
ported a non-statistically significant increase in 
number of COPD-related hospitalization; Pinnock 
et al. did not document a difference between the 
two groups [16].
Effect on hospital length of stay
This outcome was evaluated in 7 studies (Ta-
ble 3). Four studies [12,13,16,21] documented an 
increase in length of stay in telemedicine group, 
with mean differences ranging from +1.5 to +3 
days. On the contrary, a reduction in length of 
stay was reported in two studies[15,19], of 5 and 
9 days, respectively. However, only the study by 
Segrelles et al. reached statistical significance. 
Antoniades et al. found no difference in length 
of stay of the two groups.
Effect on emergency room visits
This outcome was evaluated in 6 of 12 trials 
included in our review (Table 3). With the excep-
tion of Chau et al., that found an 87% increase in 
the risk of ER visits, all the other studies reported 
a reduction in risk ranging from 17% [15] to 55% 
[19]. However, with the exception of Segrelles 
et al., none of these studies reached statistical 
significance.
Effect on mortality
Four studies evaluated this outcome, report-
ing very discordant results (Table 3): Casas et al. 
and De Toledo et a. documented an increase of 
risk of death in telemonitor group of about 18%; 
Pinnock et al. [16] and Segrelles et al. [19] report-
ed a risk reduction of 25 and 45%, respectively. 
None of these results was statistically significant.
Effect on quality of life
This outcome was evaluated in 7 studies (Ta-
ble 3). Data were not well comparable because of 
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different quality of life questionnaires were used. 
Five studies used the St. George’s Respiratory 
Questionnaire (SGRQ). A statistically and clini-
cally (>= 4 points) significant improvement  in 
SGRQ score was reported only by Koff et al. Two 
trials documented a non-statistically significant 
change >= 4 points in SGRQ in telemonitoring 
group compared with control group [18, 21] and 
four studies did not show differences in quality 
of life between groups [11,13,14,16].  
Other outcomes
Patients’ satisfaction was good in all of the 6 
trials that reported it. A non-statistically reduc-
tion in health care associated costs was reported 
in the 2 trials that evaluated this outcome.
Discussion
Our study confirms that the available ev-
idence on the effectiveness of telemedicine in 
COPD does not allow to draw definite conclu-
sions, as the studies on this topic are generally 
small and of overall poor quality, with many 
studies not providing all the data needed for a 
correct and critical interpretation of the results. 
In line with previous reviews and meta-analysis 
[22–24], we found that most evidence suggests a 
positive effect of telemonitoring on the outcomes 
taken into account, in particular with respect to 
hospital admissions and ER visits, although statis-
tical significance was reached only by few studies. 
Only Chau et al. reported a non statistically signif-
icant increase of risk in all the outcomes studied 
(hospitalizations, length of stay, ER visits).
The literature review highlights the impor-
tance of baseline treatment offered to the patients. 
In particular, it can be noticed that the benefit of 
telemedicine interventions were at best small in 
studies including education on self-care [13,16] 
or the patients were already followed in the 
center in which the experiment took place [14]. 
Interestingly, when education on self-care was 
offered only to telemedicine group, the reduction 
of hospitalizations in the intervention group was 
more evident [10,11]. Therefore, it is possible that 
part of the differences in outcomes evaluated by 
the trials may be explained by clinical services 
(education on self-management of exacerbations, 
scheduled follow-up by a physician who knows 
patients history, etc.) that may offered, either 
explicitly or implicitly, in a different quantity to 
patients in the treatment group. This hypothesis 
seems to be confirmed by the study by Pinnock et 
al., in which there was a careful optimization of 
underlying clinical services offered to both groups 
and in which telemedicine intervention had no ef-
fect. The authors concluded that baseline clinical 
services, rather than telemedicine per se, may be 
the primary determinants of improved outcomes. 
Nonetheless, some advantages of telemedicine are 
identifiable: although not statistically significant, 
a trend in improvement in all outcomes is evident 
in almost all studies, regardless of the sample size. 
Therefore, it is important to gather more informa-
tion coming from trials of adequate size in which 
the role of telemedicine per se can be separated 
by the role of clinical services associated with it. 
In line with previous reviews and meta-ana-
lysis, we did not observe any effect of telemed-
icine on mortality. These disappointing results 
only in part unexpected, as even the most prom-
ising pharmacological therapies have no clear 
effect on this outcome in COPD. For example, 
long-acting beta2-agonists (LABA) or anticholin-
ergic (LAMA) therapy did not significantly reduce 
mortality or serious adverse events [25,26]. On 
the other hand, rehabilitation appears to improve 
dispnoea, quality of life, number of exacerbations, 
subsequent hospitalizations [27,28] and mortality 
[29,30]. In this perspective, programs of telere-
habilitation may be more effective compared to 
telemedicine. Few data are available on this topic, 
but some trials are going on, showing its safety, 
feasibility [31] and improvement in dispnoea, 
quality of life and physical activity [32,33].
Despite the reported high patients satisfaction 
rate, quality of life does not appear to be signifi-
cantly improved by telemedicine interventions, 
with the only exception of Koff et al. The most 
likely explanation to this finding is that the scales 
used were disease-specific and may not have cap-
tured improvement in the overall quality of life.
The overall state of the art of telemedicine in 
COPD shows that the evidence is still sparse, with 
studies that can hardly be compared because of 
different populations (from COPD of any severi-
ty to severe COPD in long term oxygen therapy, 
enrolled in different settings),  exacerbation rate 
before enrollment, wide range of follow up peri-
ods (from 2 months to 1 year) and different types 
of technology used (from telephone interview to 
multi-parametric monitoring). Furthermore, the 
heterogeneity of measured parameters makes it 
impossible to establish which is parameter, or set 
of parameters, that is most effective for a timely 
detection of exacerbations.  Finally, the back-
ground primary care setting is different across 
studies, and this is a further issue complicating 
the data comparison.
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In addition, it is to underline that the most 
part of trials excluded patients with cognitive 
impairment and patients in palliative care;  these 
patients represent a relevant part of population, 
that can have many benefits from telemedicine, 
and that consequently should be included in 
trials, also in order to test the efficacy of telemed-
icine in a sample of the real population.
As for any review, the search strategy and 
selection criteria may have introduced bias. At 
difference with most previous reviews, we only 
included randomized clinical trials, with exclu-
sion of nonrandomized trials that are known to 
more frequently lead to positive results. This 
notwithstanding, our conclusions are in line 
with most published reviews. Furthermore, we 
did not take into account trials on telemedicine 
also including non-COPD patients. This led to the 
exclusion of some trials, as the one by Vitacca et 
al [34], that reported a reduction in hospitaliza-
tions, ER visits, urgent General Practitioner (GP) 
calls and exacerbations in the subgroup of COPD 
patients. Thus, the exclusion of this trial may 
have led to underestimate the positive effect of 
telemedicine in our review. However, no different 
conclusions about the effectiveness of telemedi-
cine were reached by reviews, such as the cited 
Cochrane review, that included this study.
Conclusions
The role of telemedicine in the management 
of COPD is still to be elucidated. More trials 
with adequate sample size and with adequate 
consideration of background clinical services 
are needed to establish its effectiveness. These 
trials should also be designed so that it will be 
possible to answer some critical questions: what 
is the population most likely to benefit from the 
intervention, what is the best set of parameters to 
collect in order to prevent adverse outcomes, and 
what the characteristics of a telemedical system 
should be in order to maximize the adherence 
of patients that are frequently elderly and with 
physical and possibly cognitive limitations.
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